tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2023-13-3s1-40-48tumors-1182Research ArticleСтатьиМолекулярная классификация рака эндометрияМолекулярная классификация рака эндометрияРаскинГ. А.РаскинГ. А.

Санкт-Петербург

Санкт-Петербург

rasking@list.ruКаурцеваА. С.КаурцеваА. С.

Санкт-Петербург

Санкт-Петербург

МухинаМ. С.МухинаМ. С.

Санкт-Петербург

Санкт-Петербург

ФГБОУ ВО «Санкт-Петербургский государственный университет»; Медицинский институт им. Березина СергеяРоссияФГБОУ ВО «Санкт-Петербургский государственный университет»; Медицинский институт им. Березина СергеяRussian FederationМедицинский институт им. Березина СергеяРоссияМедицинский институт им. Березина СергеяRussian Federation202322112023133s14048Copyright © Раскин Г.А., Каурцева А.С., Мухина М.С., 20232023Раскин Г.А., Каурцева А.С., Мухина М.С.Раскин Г.А., Каурцева А.С., Мухина М.С.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1182

   Данный обзор литературы ставит перед собой целью повысить осведомленность специалистов по обсуждаемой проблеме, а также помочь применять современную молекулярную классификацию рака эндометрия в клинической практике. В нем отражены современные рекомендации, клинические исследования и собственные данные.

   Данный обзор литературы ставит перед собой целью повысить осведомленность специалистов по обсуждаемой проблеме, а также помочь применять современную молекулярную классификацию рака эндометрия в клинической практике. В нем отражены современные рекомендации, клинические исследования и собственные данные.

рак эндометрияPOLEdMMRрак эндометрияPOLEdMMRReferencesASTEC / EN. 5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN. 5 randomised trials) : pooled trial results, systematic review, and meta-analysis. Lancet. 2009 ; 373 (9658) : 137–146. doi: 10.1016/S0140-6736(08)61767-5. [PubMed].ASTEC / EN. 5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN. 5 randomised trials) : pooled trial results, systematic review, and meta-analysis. Lancet. 2009 ; 373 (9658) : 137–146. doi: 10.1016/S0140-6736(08)61767-5. [PubMed].Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma : multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000 Apr 22;355 (9213):1404–11. doi: 10.1016/s0140-6736(00)02139-5. [PubMed].Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma : multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000 Apr 22;355 (9213):1404–11. doi: 10.1016/s0140-6736(00)02139-5. [PubMed].Kunkel TA. DNA replication fidelity. J Biol Chem. 2004 Apr 23 ; 279 (17) : 16895–8. doi: 10.1074/jbc.R400006200. [PubMed].Kunkel TA. DNA replication fidelity. J Biol Chem. 2004 Apr 23 ; 279 (17) : 16895–8. doi: 10.1074/jbc.R400006200. [PubMed].Pursell ZF, Isoz I, Lundström EB, Johansson E, Kunkel TA. Yeast DNA polymerase epsilon participates in leading-strand DNA replication. Science. 2007 ; 317 (5834) : 127–130. doi: 10.1126/science.1144067. [PubMed].Pursell ZF, Isoz I, Lundström EB, Johansson E, Kunkel TA. Yeast DNA polymerase epsilon participates in leading-strand DNA replication. Science. 2007 ; 317 (5834) : 127–130. doi: 10.1126/science.1144067. [PubMed].Nick McElhinny SA, Gordenin DA, Stith CM, Burgers PM, Kunkel TA. Division of labor at the eukaryotic replication fork. Mol Cell. 2008;30 (2):137–144. doi: 10.1016/j.molcel.2008.02.022. [PubMed].Nick McElhinny SA, Gordenin DA, Stith CM, Burgers PM, Kunkel TA. Division of labor at the eukaryotic replication fork. Mol Cell. 2008;30 (2):137–144. doi: 10.1016/j.molcel.2008.02.022. [PubMed].David N. Church, Sarah E. W. Briggs, Claire Palles, Enric Domingo, Stephen J. Kearsey, Jonathon M. Grimes, Maggie Gorman, Lynn Martin, Kimberley M. Howarth, Shirley V. Hodgson, The NSECG Collaborators, Kulvinder Kaur, Jenny Taylor, Ian P. M. Tomlinson, DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer, Human Molecular Genetics, Volume 22, Issue 14, 15 July 2013, Pages 2820–2828, doi: 10.1093/hmg/ddt131. [PubMed].David N. Church, Sarah E. W. Briggs, Claire Palles, Enric Domingo, Stephen J. Kearsey, Jonathon M. Grimes, Maggie Gorman, Lynn Martin, Kimberley M. Howarth, Shirley V. Hodgson, The NSECG Collaborators, Kulvinder Kaur, Jenny Taylor, Ian P. M. Tomlinson, DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer, Human Molecular Genetics, Volume 22, Issue 14, 15 July 2013, Pages 2820–2828, doi: 10.1093/hmg/ddt131. [PubMed].Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J ; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer : a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016 Nov ; 1 (3) : 207–216. doi: 10.1016/S2468-1253(16)30014-0. [PubMed].Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J ; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer : a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016 Nov ; 1 (3) : 207–216. doi: 10.1016/S2468-1253(16)30014-0. [PubMed].Temko D, Van Gool IC, Rayner E, et al. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 2018 ; 245 (3) : 283–296. doi: 10.1002/path.5081. [PubMed].Temko D, Van Gool IC, Rayner E, et al. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 2018 ; 245 (3) : 283–296. doi: 10.1002/path.5081. [PubMed].Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22 ; 12 (4) : 252–64. doi: 10.1038/nrc3239. [PubMed].Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22 ; 12 (4) : 252–64. doi: 10.1038/nrc3239. [PubMed].McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, Leung S, Bellone S, Wong A, Brucker SY, Lee CH, Clarke BA, Huntsman DG, Bernardini MQ, Ngeow J, Santin AD, Goodfellow P, Levine DA, Köbel M, Kommoss S, Bosse T, Gilks CB, Talhouk A. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations : An individual patient data meta-analysis. Cancer. 2021 Jul 15 ; 127 (14) : 2409–2422. doi: 10.1002/cncr.33516. [PubMed].McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, Leung S, Bellone S, Wong A, Brucker SY, Lee CH, Clarke BA, Huntsman DG, Bernardini MQ, Ngeow J, Santin AD, Goodfellow P, Levine DA, Köbel M, Kommoss S, Bosse T, Gilks CB, Talhouk A. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations : An individual patient data meta-analysis. Cancer. 2021 Jul 15 ; 127 (14) : 2409–2422. doi: 10.1002/cncr.33516. [PubMed].Cao, W., Ma, X., Fischer, J. V. et al. Immunotherapy in endometrial cancer : rationale, practice and perspectives. Biomark Res 9, 49 (2021). doi: 10.1186/s40364-021-00301-z. [PubMed].Cao, W., Ma, X., Fischer, J. V. et al. Immunotherapy in endometrial cancer : rationale, practice and perspectives. Biomark Res 9, 49 (2021). doi: 10.1186/s40364-021-00301-z. [PubMed].Pećina-Šlaus N, Kafka A, Salamon I, Bukovac A. Mismatch Repair Pathway, Genome Stability and Cancer. Front Mol Biosci. 2020 ; 7 : 122. Published 2020 Jun 26. doi: 10.3389/fmolb.2020.00122. [PubMed].Pećina-Šlaus N, Kafka A, Salamon I, Bukovac A. Mismatch Repair Pathway, Genome Stability and Cancer. Front Mol Biosci. 2020 ; 7 : 122. Published 2020 Jun 26. doi: 10.3389/fmolb.2020.00122. [PubMed].Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian Y, O’Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2019 Feb 1 ; 37 (4) : 286–295. doi: 10.1200/JCO.18.00283. [PubMed].Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian Y, O’Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2019 Feb 1 ; 37 (4) : 286–295. doi: 10.1200/JCO.18.00283. [PubMed].Pai RK, Plesec TP, Abdul-Karim FW, Yang B, Marquard J, Shadrach B, Roma AR. Abrupt loss of MLH1 and PMS2 expression in endometrial carcinoma : molecular and morphologic analysis of 6 cases. Am J Surg Pathol. 2015 Jul ; 39 (7) : 993–9. doi: 10.1097/PAS.0000000000000415. [PubMed].Pai RK, Plesec TP, Abdul-Karim FW, Yang B, Marquard J, Shadrach B, Roma AR. Abrupt loss of MLH1 and PMS2 expression in endometrial carcinoma : molecular and morphologic analysis of 6 cases. Am J Surg Pathol. 2015 Jul ; 39 (7) : 993–9. doi: 10.1097/PAS.0000000000000415. [PubMed].Watkins JC, Nucci MR, Ritterhouse LL, Howitt BE, Sholl LM. Unusual Mismatch Repair Immunohistochemical Patterns in Endometrial Carcinoma. Am J Surg Pathol. 2016 Jul ; 40 (7) : 909–16. doi: 10.1097/PAS.0000000000000663. [PubMed].Watkins JC, Nucci MR, Ritterhouse LL, Howitt BE, Sholl LM. Unusual Mismatch Repair Immunohistochemical Patterns in Endometrial Carcinoma. Am J Surg Pathol. 2016 Jul ; 40 (7) : 909–16. doi: 10.1097/PAS.0000000000000663. [PubMed].Hashmi AA, Mudassir G, Hashmi RN, Irfan M, Asif H, Khan EY, Abu Bakar SM, Faridi N. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters. Asian Pac J Cancer Prev. 2019 Sep 1 ; 20 (9) : 2601–2606. doi: 10.31557/APJCP.2019.20.9.2601. [PubMed].Hashmi AA, Mudassir G, Hashmi RN, Irfan M, Asif H, Khan EY, Abu Bakar SM, Faridi N. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters. Asian Pac J Cancer Prev. 2019 Sep 1 ; 20 (9) : 2601–2606. doi: 10.31557/APJCP.2019.20.9.2601. [PubMed].Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One. 2010 Feb 24 ; 5 (2) : e9393. doi: 10.1371/journal.pone.0009393. Erratumin : PLoS One. 2010 ; 5 (3). URL: https://pubmed.ncbi.nlm.nih.gov/20195377/. [PubMed].Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One. 2010 Feb 24 ; 5 (2) : e9393. doi: 10.1371/journal.pone.0009393. Erratumin : PLoS One. 2010 ; 5 (3). URL: https://pubmed.ncbi.nlm.nih.gov/20195377/. [PubMed].McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015 May ; 137 (2) : 306–10. doi: 10.1016/j.ygyno.2015.01.541. [PubMed].McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, McAlpine JN. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015 May ; 137 (2) : 306–10. doi: 10.1016/j.ygyno.2015.01.541. [PubMed].Loughrey MB, McGrath J, Coleman HG, Bankhead P, Maxwell P, McGready C, Bingham V, Humphries MP, Craig SG, McQuaid S, Salto-Tellez M, James JA. Identifying mismatch repair-deficient colon cancer : near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series. Histopathology. 2021 Feb ; 78 (3) : 401–413. doi: 10.1111/his.14233. [PubMed].Loughrey MB, McGrath J, Coleman HG, Bankhead P, Maxwell P, McGready C, Bingham V, Humphries MP, Craig SG, McQuaid S, Salto-Tellez M, James JA. Identifying mismatch repair-deficient colon cancer : near-perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population-based series. Histopathology. 2021 Feb ; 78 (3) : 401–413. doi: 10.1111/his.14233. [PubMed].Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MDM, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, DingL.Mutational landscape and significance across 12 major cancer types. Nature. 2013 Oct 17 ; 502 (7471) : 333–339. doi: 10.1038/nature12634. [PubMed].Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MDM, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, DingL.Mutational landscape and significance across 12 major cancer types. Nature. 2013 Oct 17 ; 502 (7471) : 333–339. doi: 10.1038/nature12634. [PubMed].Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol. 2011 Jan ; 223 (2) : 116–26. doi: 10.1002/path.2784. [PumMed].Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol. 2011 Jan ; 223 (2) : 116–26. doi: 10.1002/path.2784. [PumMed].Shaikh MF, Morano WF, Lee J, Gleeson E, Babcock BD, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB. Emerging Role of MDM2 as Target for Anti-Cancer Therapy : A Review. Ann Clin Lab Sci. 2016 Dec ; 46 (6) : 627–634. PMID: 27993876. [PubMed].Shaikh MF, Morano WF, Lee J, Gleeson E, Babcock BD, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB. Emerging Role of MDM2 as Target for Anti-Cancer Therapy : A Review. Ann Clin Lab Sci. 2016 Dec ; 46 (6) : 627–634. PMID: 27993876. [PubMed].Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene : Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011 Apr ; 2 (4) : 466–74. doi: 10.1177/1947601911408889. [PubMed].Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene : Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011 Apr ; 2 (4) : 466–74. doi: 10.1177/1947601911408889. [PubMed].Tuna M, Ju Z, Yoshihara K, Amos CI, Tanyi JL, Mills GB. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. Br J Cancer. 2020 Feb ; 122 (3) : 405–412. doi: 10.1038/s41416-019-0654-8. [PubMed].Tuna M, Ju Z, Yoshihara K, Amos CI, Tanyi JL, Mills GB. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. Br J Cancer. 2020 Feb ; 122 (3) : 405–412. doi: 10.1038/s41416-019-0654-8. [PubMed].Schultheis AM, Martelotto LG, De Filippo MR, Piscuglio S, Ng CK, Hussein YR, Reis-Filho JS, Soslow RA, Weigelt B. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int J Gynecol Pathol. 2016 Jul ; 35 (4) : 289–300. doi: 10.1097/PGP.0000000000000243. [PubMed].Schultheis AM, Martelotto LG, De Filippo MR, Piscuglio S, Ng CK, Hussein YR, Reis-Filho JS, Soslow RA, Weigelt B. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int J Gynecol Pathol. 2016 Jul ; 35 (4) : 289–300. doi: 10.1097/PGP.0000000000000243. [PubMed].Soussi T, Leroy B, Taschner PE. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. Hum Mutat. 2014 Jun ; 35 (6) : 766–78. doi: 10.1002/humu.22561. [PubMed].Soussi T, Leroy B, Taschner PE. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. Hum Mutat. 2014 Jun ; 35 (6) : 766–78. doi: 10.1002/humu.22561. [PubMed].Obata T, Nakamura M, Mizumoto Y, Iizuka T, Ono M, Terakawa J, Daikoku T, Fujiwara H. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. PLoS One. 2017 Nov 30 ; 12 (11) : e0188641. doi: 10.1371/journal.pone.0188641. [PubMed].Obata T, Nakamura M, Mizumoto Y, Iizuka T, Ono M, Terakawa J, Daikoku T, Fujiwara H. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. PLoS One. 2017 Nov 30 ; 12 (11) : e0188641. doi: 10.1371/journal.pone.0188641. [PubMed].Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas : Toward Increased Reproducibility. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1 (Iss 1 Suppl 1):S123-S131. doi: 10.1097/PGP.0000000000000488. [PubMed].Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas : Toward Increased Reproducibility. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1 (Iss 1 Suppl 1):S123-S131. doi: 10.1097/PGP.0000000000000488. [PubMed].Schultheis AM, Martelotto LG, De Filippo MR, Piscuglio S, Ng CK, Hussein YR, Reis-Filho JS, Soslow RA, Weigelt B. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int J Gynecol Pathol. 2016 Jul ; 35 (4) : 289–300. doi: 10.1097/PGP.0000000000000243. [PubMed].Schultheis AM, Martelotto LG, De Filippo MR, Piscuglio S, Ng CK, Hussein YR, Reis-Filho JS, Soslow RA, Weigelt B. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Int J Gynecol Pathol. 2016 Jul ; 35 (4) : 289–300. doi: 10.1097/PGP.0000000000000243. [PubMed].Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P. L1CAM : a major driver for tumor cell invasion and motility. Cell Adh Migr. 2012 Jul-Aug ; 6 (4) : 374–84. doi: 10.4161/cam.20832. [PubMed].Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P. L1CAM : a major driver for tumor cell invasion and motility. Cell Adh Migr. 2012 Jul-Aug ; 6 (4) : 374–84. doi: 10.4161/cam.20832. [PubMed].Chen J, Gao F, Liu N. L1CAM promotes epithelial to mesenchymal transition and formation of cancer initiating cells in human endometrial cancer. Exp Ther Med. 2018 Mar ; 15 (3) : 2792–2797. doi: 10.3892/etm.2018.5747. [PubMed].Chen J, Gao F, Liu N. L1CAM promotes epithelial to mesenchymal transition and formation of cancer initiating cells in human endometrial cancer. Exp Ther Med. 2018 Mar ; 15 (3) : 2792–2797. doi: 10.3892/etm.2018.5747. [PubMed].Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018 Aug ; 119 (4) : 480–486. doi: 10.1038/s41416-018-0187-6. [PubMed].Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018 Aug ; 119 (4) : 480–486. doi: 10.1038/s41416-018-0187-6. [PubMed].Altevogt P, Doberstein K, Fogel M. L1CAM in human cancer. Int J Cancer. 2016 Apr 1 ; 138 (7) : 1565–76. doi: 10.1002/ijc.29658. [PubMed].Altevogt P, Doberstein K, Fogel M. L1CAM in human cancer. Int J Cancer. 2016 Apr 1 ; 138 (7) : 1565–76. doi: 10.1002/ijc.29658. [PubMed].Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M. L1CAM in early-stage type I endometrial cancer : results of a large multicenter evaluation. J Natl Cancer Inst. 2013 Aug 7 ; 105 (15) : 1142–50. doi: 10.1093/jnci/djt144. [PubMed].Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M. L1CAM in early-stage type I endometrial cancer : results of a large multicenter evaluation. J Natl Cancer Inst. 2013 Aug 7 ; 105 (15) : 1142–50. doi: 10.1093/jnci/djt144. [PubMed].Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Mod Pathol. 2016 Feb ; 29 (2) : 174–81. doi: 10.1038/modpathol.2015.147. [PubMed].Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Mod Pathol. 2016 Feb ; 29 (2) : 174–81. doi: 10.1038/modpathol.2015.147. [PubMed].Jung YS, Park JI. Wnt signaling in cancer : therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020 Feb ; 52 (2) : 183–191. doi: 10.1038/s12276-020-0380-6. [PubMed].Jung YS, Park JI. Wnt signaling in cancer : therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020 Feb ; 52 (2) : 183–191. doi: 10.1038/s12276-020-0380-6. [PubMed].Yang K, Wang X, Zhang H, Wang Z, Nan G, Li Y, Zhang F, Mohammed MK, Haydon RC, Luu HH, Bi Y, He TC. The evolving roles of canonical WNT signaling in stem cells and tumorigenesis : implications in targeted cancer therapies. [PubMed].Yang K, Wang X, Zhang H, Wang Z, Nan G, Li Y, Zhang F, Mohammed MK, Haydon RC, Luu HH, Bi Y, He TC. The evolving roles of canonical WNT signaling in stem cells and tumorigenesis : implications in targeted cancer therapies. [PubMed].Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, Broaddus RR. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017 Jul ; 30 (7) : 1032–1041. doi: 10.1038/modpathol.2017.15. [PubMed].Kurnit KC, Kim GN, Fellman BM, Urbauer DL, Mills GB, Zhang W, Broaddus RR. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol. 2017 Jul ; 30 (7) : 1032–1041. doi: 10.1038/modpathol.2017.15. [PubMed].Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, ZhangW.Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014 Sep 10 ; 106 (9) : dju245. doi: 10.1093/jnci/dju245. [PubMed].Liu Y, Patel L, Mills GB, Lu KH, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, ZhangW.Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014 Sep 10 ; 106 (9) : dju245. doi: 10.1093/jnci/dju245. [PubMed].Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res. 2016 Aug 15 ; 22 (16) : 4215–24. doi: 10.1158/1078-0432.CCR-15-2878. [PubMed].Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res. 2016 Aug 15 ; 22 (16) : 4215–24. doi: 10.1158/1078-0432.CCR-15-2878. [PubMed].Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, Liles G, Karlan B, Köbel M, Lee CH, Soslow RA. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015 Apr ; 28 (4) : 505–14. doi: 10.1038/modpathol.2014.143. [PubMed].Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, Liles G, Karlan B, Köbel M, Lee CH, Soslow RA. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015 Apr ; 28 (4) : 505–14. doi: 10.1038/modpathol.2014.143. [PubMed].Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase ε (POLE) mutations in endometrial cancer : clinical outcomes and implications for Lynch syndrome testing. Cancer. 2015 Feb 1 ; 121 (3) : 386–94. doi: 10.1002/cncr.29046. [PubMed].Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase ε (POLE) mutations in endometrial cancer : clinical outcomes and implications for Lynch syndrome testing. Cancer. 2015 Feb 1 ; 121 (3) : 386–94. doi: 10.1002/cncr.29046. [PubMed].Talhouk A, McAlpine JN. New classification of endometrial cancers : the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016 Dec 13 ; 3 : 14. doi: 10.1186/s40661-016-0035-4. [PubMed].Talhouk A, McAlpine JN. New classification of endometrial cancers : the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016 Dec 13 ; 3 : 14. doi: 10.1186/s40661-016-0035-4. [PubMed].Han J, Kim HS. Abdominopelvic Metastasis of Endometrial Serous Carcinoma Initially Misdiagnosed as Early-Stage Low-Grade Endometrioid Carcinoma : The Importance of Recognizing Minimal Uterine Serous Carcinoma. Case Rep Oncol. 2020 Dec 23 ; 13 (3) : 1537–1544. doi: 10.1159/000511701. [PubMed].Han J, Kim HS. Abdominopelvic Metastasis of Endometrial Serous Carcinoma Initially Misdiagnosed as Early-Stage Low-Grade Endometrioid Carcinoma : The Importance of Recognizing Minimal Uterine Serous Carcinoma. Case Rep Oncol. 2020 Dec 23 ; 13 (3) : 1537–1544. doi: 10.1159/000511701. [PubMed].Carvalho JP, Del Giglio A, Achatz MI, Carvalho FM. Complete Clinical Response in Stage IVB Endometrioid Endometrial Carcinoma after First-Line Pembrolizumab Therapy : Report of a Case with Isolated Loss of PMS2 Protein. Case Rep Oncol. 2020 Sep 7 ; 13 (3) : 1067–1074. doi: 10.1159/000510000. [PubMed].Carvalho JP, Del Giglio A, Achatz MI, Carvalho FM. Complete Clinical Response in Stage IVB Endometrioid Endometrial Carcinoma after First-Line Pembrolizumab Therapy : Report of a Case with Isolated Loss of PMS2 Protein. Case Rep Oncol. 2020 Sep 7 ; 13 (3) : 1067–1074. doi: 10.1159/000510000. [PubMed].

The authors declare that there are no conflicts of interest present.